Eligibility

All abstracts must have been submitted by 11-2-18, at 11:59 p.m., Central European Time.
To submit an abstract the following criteria must be met:

  • Abstracts must be submitted through the online submission system
  • The abstract pertains to cardiovascular tissue engineering, focussing on heart valve tissue engineering
  • The abstract must be limited to 350 words not including authors or title
  • The abstract must be written in clear English. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission.
  • The first author of the abstract will serve as the presenting author as well as the primary contact for all correspondence unless otherwise specified
The following criteria will make an abstract ineligible for presentation at the event:
  • The data have been previously made available through major search engines
  • Updated analyses will be considered if the abstract is a significant extension of previous work

General Guidelines
  • The presenting author is responsible for the following:
    • Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
    • Notifying all co-authors of any additions, deletions, and changes to the program.
    • Obtaining all the conflict-of-interest disclosure and copyright transfer information from co-authors.
    • Forwarding all correspondence to all co-authors.
  • Each abstract author agrees and certifies that he or she:
    • has read all the rules and agrees to be bound by them,
    • waives any and all claims against the International Conference on Heart Valve Tissue Engineering and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
  • Abstracts submitted to the general submission section will be considered as oral presentations only.
  • Abstracts which are not chosen for oral presentation sessions, will automatically be considered for poster presentation
  • Authors assign copyright of the abstract to the International Conference on Heart Valve Tissue Engineering upon submission. This means that an identical abstract may not be published or submitted to another organisation or event.
  • All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
  • Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid
  • No revisions to the abstract may be made after the abstract submission deadline.
  • The presentation at the annual meeting must reflect the submitted abstract as closely as possible.
  • The abstract title, authorship, and scientific content of the presentation must match the submitted abstract. Updates on results may be added.
  • Any technical questions regarding the submission process should be directed to abstract@ictehv.com
Abstract Review and Selection Process
  1. After the submission deadline, eligible abstracts will be made available to the abstract reviewers for review and scoring. Final decisions will be made by the Program Committee by 1-3-18. Notification of the final decision will be sent by email to the corresponding author.
  2. Incomplete abstracts will not be reviewed.
  3. We reserve the right to withdraw abstracts that are in violation of our policies and guidelines as stipulated on our website.
Author Responsibility Regarding Conflict-of-Interest Disclosure
  1. The presenting author is responsible for obtaining disclosure information from all co-authors.
  2. Incomplete abstracts will not be reviewed.
  3. This includes relationships with pharmaceutical companies, biomedical device manufacturers, or other companies whose products or services are related to the subject matter of the presentation topic. If no relevant relationships exist, this must be stated as well.
Contact Information
  1. Your name, degree, institution, address, phone number, and email address must be provided. As the corresponding author, you will receive all future correspondence.
  2. The corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission.
  3. Names of co-authors and institutions must be provided. Changes will not be made to the spelling of authors' names after the submission deadline.
Use of Product Names
  1. Non-proprietary (generic/scientific) names should be used and should be lowercase.
  2. If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. We reserve the right to replace proprietary names with generic names to adhere to this policy.
Abbreviations

Please use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.

Abstract Body, Tables, and Figures
  1. Abstracts will be typeset from the text submitted by the author without copy editing changes. It is the responsibility of the author to proofread the abstract carefully.
  2. The body of the abstract, excluding tables, must not exceed 350 words. Spaces are not included in this number. Title, authors’ names, affiliations, figures, and tables are not included in the character count.
  3. The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.
  4. Do not use bold type or underline formatting. Italic type is acceptable.
  5. Text may be in multiple paragraphs.
  6. Take care to use appropriate special Greek and mathematical symbols where needed.
  7. Any references should be noted as citations within the text and not as footnotes at the end.